Information  X 
Enter a valid email address

Hutchison China Medi (HCM)

  Print      Mail a friend

Thursday 10 October, 2019

Hutchison China Medi

Grant of share options under share option scheme

RNS Number : 4824P
Hutchison China Meditech Limited
10 October 2019

 Grant of Share Options under Share Option Scheme


London: Thursday, October 10, 2019: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that on October 9, 2019, it granted share options under the Share Option Scheme conditionally adopted by Chi-Med at its Annual General Meeting in 2015 (the "2015 HCML Share Option Scheme").


Chi-Med granted 1,735,000 share options under its 2015 HCML Share Option Scheme to certain employees to subscribe for Ordinary Shares subject to the acceptance of the grantees.  Details of such share options granted prescribed are as follows:


Date of grant


October 9, 2019


Exercise price of share options granted


GBP2.978 per Ordinary Share


Number of share options granted


1,735,000 (each share option shall entitle the holder thereof to subscribe for one Ordinary Share)


Closing market price of Ordinary Shares on the date of grant



GBP2.8775 per Ordinary Share


Validity period of the share options


From October 9, 2019 to October 8, 2029



About Chi-Med


Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical company which researches, develops, manufactures and markets pharmaceutical products. Its Innovation Platform, Hutchison MediPharma, has about 470 scientists and staff focusing on discovering, developing and commercializing targeted therapeutics and immunotherapies in oncology and autoimmune diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world. Chi-Med's Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products, covering an extensive network of hospitals across China.


Chi-Med is headquartered in Hong Kong and is dual-listed on the AIM market of the London Stock Exchange and the Nasdaq Global Select Market. For more information, please visit:



Forward-Looking Statements


This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements involve risks and uncertainties.  Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof.  For further discussion of these and other risks, see Chi-Med's filings with the U.S. Securities and Exchange Commission and on AIM.  Chi-Med undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.





Investor Enquiries


Mark Lee, Senior Vice President

+852 2121 8200

Annie Cheng, Vice President


+1 (973) 567 3786

David Dible, Citigate Dewe Rogerson

+44 7967 566 919 (Mobile)
[email protected]

Xuan Yang, Solebury Trout

+1 (415) 971 9412 (Mobile)
[email protected]



Media Enquiries


UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson

+44 7973 611 888 (Mobile)
[email protected]

Americas - Brad Miles, Solebury Trout

+1 (917) 570 7340 (Mobile)
[email protected]

Hong Kong & Asia ex-China

- Joseph Chi Lo, Brunswick

+852 9850 5033 (Mobile)
[email protected]

- Zhou Yi, Brunswick      

+852 9783 6894 (Mobile)
y[email protected]

Mainland China - Sam Shen, Edelman

+86 136 7179 1029 (Mobile)
[email protected]



Nominated Advisor


Atholl Tweedie, Panmure Gordon (UK) Limited

+44 (20) 7886 2500



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t